Skip to main content
Clinical Trials/IRCT20190714044201N1
IRCT20190714044201N1
Completed
Phase 2

Safety and efficacy of Amniotic Membrane in Asherman's syndrome management

Sarem Fertility and Infertility Research Center0 sites10 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Sarem Fertility and Infertility Research Center
Enrollment
10
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Sarem Fertility and Infertility Research Center

Eligibility Criteria

Inclusion Criteria

  • Asherman's patients with intrauterine adhesions and endometrial atrophy
  • endometrial thickness of less than 5 mm
  • normal functioning of the heart kidneys and lungs
  • wish to complete the study

Exclusion Criteria

  • Unwilling to get pregnant
  • Genital tract inflammation
  • Cardiovascular diseases
  • Hormonal Problems Contraceptive Indication of Relative Hormone Therapy
  • Gastrointestinal diseases
  • prohibits estrogen use
  • liver or chronic hepatic failure
  • Immune system diseases such as lupus, ...
  • Past and present cancer
  • Positive serologic evidence of previous or current hepatitis B and C infection as well as HIV and HTLV

Outcomes

Primary Outcomes

Not specified

Similar Trials